JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma

Background JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM).Patients and methods Patients with untreated, unresectable MPM with an Eastern Cooperative Oncology Group (ECOG) performance...

Full description

Saved in:
Bibliographic Details
Main Authors: Nobukazu Fujimoto, Yosuke Miyamoto, Sae Wada, Katsuyuki Hotta, Toshiyuki Kozuki, Keisuke Aoe, Jun Sakurai, Michihiro Yoshida, Daijiro Harada
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e003288.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items